"PTEN Phosphohydrolase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipid phosphatase that contains a C2 DOMAIN and acts on phosphatidylinositol-3,4,5-trisphosphate to regulate various SIGNAL TRANSDUCTION PATHWAYS. It modulates CELL GROWTH PROCESSES; CELL MIGRATION; and APOPTOSIS. Mutations in PTEN are associated with COWDEN DISEASE and PROTEUS SYNDROME as well as NEOPLASTIC CELL TRANSFORMATION.
| Descriptor ID |
D051059
|
| MeSH Number(s) |
D08.811.277.352.650.850 D12.776.476.590 D12.776.624.776.695
|
| Concept/Terms |
PTEN Phosphohydrolase- PTEN Phosphohydrolase
- Phosphohydrolase, PTEN
- PTEN Protein
- Phosphatase and Tensin Homologue on Chromosome Ten Protein
- PTEN Phosphatase
- Phosphatase, PTEN
- MMAC1 Protein
- PTEN Protein Phosphatase
- Phosphatase, PTEN Protein
- Protein Phosphatase, PTEN
- Mutated In Multiple Advanced Cancers 1 Protein
|
Below are MeSH descriptors whose meaning is more general than "PTEN Phosphohydrolase".
Below are MeSH descriptors whose meaning is more specific than "PTEN Phosphohydrolase".
This graph shows the total number of publications written about "PTEN Phosphohydrolase" by people in this website by year, and whether "PTEN Phosphohydrolase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2005 | 1 | 4 | 5 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 1 | 2 |
| 2008 | 7 | 0 | 7 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 1 | 8 |
| 2011 | 4 | 7 | 11 |
| 2012 | 4 | 12 | 16 |
| 2013 | 5 | 6 | 11 |
| 2014 | 4 | 5 | 9 |
| 2015 | 9 | 3 | 12 |
| 2016 | 5 | 4 | 9 |
| 2017 | 10 | 6 | 16 |
| 2018 | 5 | 2 | 7 |
| 2019 | 4 | 1 | 5 |
| 2020 | 4 | 4 | 8 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "PTEN Phosphohydrolase" by people in Profiles.
-
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026 Jan; 37(1):53-68.
-
Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex. Clin Cancer Res. 2025 Jan 17; 31(2):234-244.
-
Overexpression of ELF3 in the PTEN-deficient lung epithelium promotes lung cancer development by inhibiting ferroptosis. Cell Death Dis. 2024 Dec 18; 15(12):897.
-
Using multiplexed functional data to reduce variant classification inequities in underrepresented populations. Genome Med. 2024 Dec 03; 16(1):143.
-
eEF1A2 promotes PTEN-GSK3?-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal. 2024 03 05; 17(826):eadh4475.
-
The Rare and Atypical Diabetes Network (RADIANT) Study: Design and Early Results. Diabetes Care. 2023 06 01; 46(6):1265-1270.
-
MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nat Commun. 2022 01 11; 13(1):245.
-
Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice. Mol Oncol. 2022 03; 16(5):1184-1199.
-
MEX3D is an oncogenic driver in prostate cancer. Prostate. 2021 11; 81(15):1202-1213.
-
Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases. Melanoma Res. 2021 06 01; 31(3):264-267.